Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford is the academic lead institution for StemBANCC. This 5-year research programme funded by the Innovative Medicines Initiative (IMI) involving academic and industry partners across 11 countries with the objective of developing human induced pluripotent stem cells as a platform for drug discovery.

Oxford stembancc 2013 stem cells for drug discovery
StemBANCC Research Programme


1. Access to well characterised, genetically diverse iPSC-derived cell types for Pharma and academia in Europe

  • Provision of bio-materials
  • Provision of baseline bio-data

2. Disease biology with focus on neurological disorders (PNS, CNS) and diabetes

  • Recreate the cellular phenotypes of disease using iPSC-derived cells

3. Cell-based assays for predictive toxicology

  • Predictive toxicology (focus on liver, heart, kidney)

4. Assays for the study of disease biology, and compound efficacy and toxicity

  • Translating phenotypes into robust drug screening assays

5. Optimise protocols for the appropriate culture, differentiation, expansion and maintenance of stem cell derived cell-type

6. Foster the implementation of a central test facility for the maintenance of the bio-bank beyond the funded period